* BioXcel Therapeutics Inc BTAI.OQ reported a quarterly
adjusted
loss of 21 cents per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of $-1.83. The mean expectation of six analysts
for the quarter was for a loss of 71 cents per share. Wall
Street expected results to range from -79 cents to -54 cents per
share.
* Revenue rose 141.6% to $1.10 million from a year ago;
analysts
expected $759.20 thousand.
* BioXcel Therapeutics Inc's reported EPS for the quarter
was a
loss of 21 cents.
* The company reported a quarterly loss of $8.3 million.
* BioXcel Therapeutics Inc shares had fallen by 28.1% this
quarter and lost 68.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 4.7%
in the last three months.
* In the last 30 days, there have been no negative revisions
of
earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for BioXcel
Therapeutics Inc is $7.00
This summary was machine generated from LSEG data August 6 at
01:52 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jan. 1 0001 -0.71 -0.21 Beat
Mar. 31 2024 -0.70 -0.87 Missed
Dec. 31 2023 -0.91 -0.76 Beat
Sep. 30 2023 -1.30 -1.72 Missed